 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
465 News |  |
- ||| AUTO4 / Autolus
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma (clinicaltrials.gov) - May 14, 2025
P1/2, N=20, Completed, Sponsor: Autolus Limited
Active, not recruiting --> Completed | N=200 --> 20 | Trial completion date: Oct 2026 --> Dec 2024 | Trial primary completion date: Oct 2026 --> Dec 2024
- || AUTO4 / Autolus
Enrollment closed, Trial completion date, Trial primary completion date: Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma (clinicaltrials.gov) - Sep 24, 2024
P1/2, N=200, Active, not recruiting, Sponsor: Autolus Limited
Active, not recruiting --> Completed | N=200 --> 20 | Trial completion date: Oct 2026 --> Dec 2024 | Trial primary completion date: Oct 2026 --> Dec 2024 Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Oct 2026 | Trial primary completion date: Jul 2023 --> Oct 2026
- |||||| AUTO4 / Autolus
Clinical: Findings from the AUTO4-TL1 trial demonstrated that AUTO4 showed early clinical activity and tolerability in relapsed/refractory TRBC1-positive peripheral T-cell lymphoma. @CwynKate @uclh @icmlugano #ICML17 #lymsm #oncology https://t.co/witNC7xJW1 (Twitter) - Jun 28, 2023
- ||||| AUTO4 / Autolus
Update of #AUTO4 from @CwynKate, TRBC1 targetting CAR-T for T cell lymphoma. Bench to bedside translational science @uclcancer @uclh @paulmaciocia (Twitter) - Jun 15, 2023
- |||||| AUTO4 / Autolus
Clinical, P2 data, CAR T-Cell Therapy: #17ICML @CwynKate describes the clinical findings of AUTO4, a CAR T-cell product targeting TRBC1 for patients with TRBC1-positive PTCL. Follow-up data show AUTO4 was well tolerated without dose limiting toxicity. The study is ongoing to define phase 2 dose #lymsm #leusm #lymphoma (Twitter) - Jun 14, 2023
- |||| AUTO4 / Autolus
Delighted to present our exciting Ph1 data ‘FIRST IN HUMAN STUDY OF AUTO4, TRBC1‐TARGETING CART, IN R/R TRBC1+ve PTCL’ at #17ICML Credit to co-I: @gloria_iacoboni #MartinPule #EleniTholouli @tobiasmenne2 #DavidIrvine @paulmaciocia https://t.co/tx2CriTWKg (Twitter) - Jun 11, 2023
- AUTO4 / Autolus
First in human study of AUTO4, a TRBC1-tragetting CART T cell therapy in Relpased/Refractory TRBC1-Positive Peripheral T-cell Lymphoma (Room A) - May 4, 2023 - Abstract #ICML2023ICML_153;
- || AUTO4 / Autolus
AUTO4 is one of the most unique treatments for Autolus compared to competition. The persistence of ongoing 6 and 9 months is encouraging too, so ditching it would be wrong. (Twitter) - Nov 5, 2022
- AUTO4 / Autolus
First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_6464;
P1/2
Early responses are encouraging, although no CAR T cell expansion was seen in peripheral blood which may translate to responses that are not durable. To address this, optimisation of the AUTO4 manufacturing process has been performed, resulting in a product with a more naïve phenotype.
- AUTO4 / Autolus
SAFETY AND PRELIMINARY EFFICACY FINDINGS OF AUTO4, A TRBC1-TARGETTING CAR, IN RELAPSED/REFRACTORY TRBC1 POSITIVE SELECTED T CELL NON-HODGKIN LYMPHOMA (Hall Strauss 1-2) - May 13, 2022 - Abstract #EHA2022EHA_2702;
P1/2
Patients received lymphodepletion with fludarabine (30mg/m 2 x4, day-6 to day-3) and cyclophosphamide (500mg/m 2 x2 on day-6 and day-5) (Flu/Cy) prior to AUTO4 infusion on Day 0...Early data shows encouraging response rates. U pdated data and longer follow up will be presented.
- ||| AUTO4 / Autolus
Enrollment change, Trial completion date, Trial primary completion date: Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma (clinicaltrials.gov) - Feb 16, 2022
P1/2, N=200, Recruiting, Sponsor: Autolus Limited
U pdated data and longer follow up will be presented. N=55 --> 200 | Trial completion date: Dec 2023 --> Jul 2025 | Trial primary completion date: Jun 2022 --> Jul 2023
- || AUTO4 / Autolus
Trial completion date, Trial primary completion date: Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma (clinicaltrials.gov) - Oct 28, 2020
P1/2, N=55, Recruiting, Sponsor: Autolus Limited
N=55 --> 200 | Trial completion date: Dec 2023 --> Jul 2025 | Trial primary completion date: Jun 2022 --> Jul 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jul 2021 --> Jun 2022
- | AUTO4 / Autolus
Enrollment open: Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma (clinicaltrials.gov) - Jul 19, 2018
P1/2, N=55, Recruiting, Sponsor: Autolus Limited
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jul 2021 --> Jun 2022 Not yet recruiting --> Recruiting
- | AUTO4 / Autolus
New P1/2 trial: Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma (clinicaltrials.gov) - Jul 18, 2018
P1/2, N=55, Not yet recruiting, Sponsor: Autolus Limited